The London Life Sciences team advised Acorai on its $4.5 million oversubscribed series seed financing round. The round was led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund and other US investors. Significant follow-on investment was taken from existing investors from across Sweden and the EU.
Acorai is developing a non-invasive intracardiac pressure monitoring device to improve heart failure management for more than 64 million patients worldwide. Acorai’s monitoring system was designated a breakthrough device by the FDA in 2023 and is built upon the patented SAVE Sensor System, a proprietary, non-invasive hardware & machine learning platform. The company plans to use the funding to finance its clinical studies and move towards regulatory approval.
The Goodwin team was led by Sophie McGrath, Richard Bloomfield, Matthew Lee and Hattie Muncey (Corporate / Life Sciences), with assistance from Morag Peberdy (Intellectual Property, Transactions and Licensing / Life Sciences).
For more details, please read the press release.